Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "BAL-Pharma"

442 News Found

Budget 2025: Industry welcomes customs duty exemptions on 36 life-saving drugs and medicines
Policy | February 01, 2025

Budget 2025: Industry welcomes customs duty exemptions on 36 life-saving drugs and medicines

The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25


Strides reports 14.6% growth in Q3 FY25 revenue
News | January 31, 2025

Strides reports 14.6% growth in Q3 FY25 revenue

EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore


Piramal Pharma Q3 FY25 revenue up 13%
News | January 30, 2025

Piramal Pharma Q3 FY25 revenue up 13%

CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business


Mankind Pharma launches 45-day healthcare mission at Mahakumbh
Healthcare | January 28, 2025

Mankind Pharma launches 45-day healthcare mission at Mahakumbh

The camp, operational daily from 12 PM to 4 PM, offers free health check-ups, blood pressure monitoring


AstraZeneca plans US$ 570 million investment in Canada
News | January 27, 2025

AstraZeneca plans US$ 570 million investment in Canada

700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies


Piramal Critical Care announces US launch of Chlorpromazine Hydrochloride for Injection
News | January 23, 2025

Piramal Critical Care announces US launch of Chlorpromazine Hydrochloride for Injection

The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care


Zydus announces USFDA Orphan Drug Designation to Usnoflast for treatment of ALS
Drug Approval | January 23, 2025

Zydus announces USFDA Orphan Drug Designation to Usnoflast for treatment of ALS

The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS


Strides Pharma debuts with ESG rating of 76/100 in the S&P Global’s CSA 2024
Sustainability | January 23, 2025

Strides Pharma debuts with ESG rating of 76/100 in the S&P Global’s CSA 2024

Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance


Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflas
Drug Approval | January 19, 2025

Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflas

This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo


Dr. Kathiresan Rajasekar appointed President – International Business, Gufic Biosciences
People | January 16, 2025

Dr. Kathiresan Rajasekar appointed President – International Business, Gufic Biosciences

With over 28 years of experience in the pharmaceutical industry, he is a seasoned Techno? Commercial professional and accomplished top management leader